HealthDay News — In a clinical guideline issued by the American College of Gastroenterology and published in the January issue of the American Journal of Gastroenterology, recommendations are ...

Following receipt of dupilumab for 24 weeks, desensitization to peanut exposure in most children/adolescents with peanut ...

A multi-institutional study led by researchers at Children's Hospital of Philadelphia (CHOP) is the first to identify one of ...

First described nearly 20 years ago, eosinophilic esophagitis (EoE) is an inflammatory disease of the esophagus characterized by eosinophilic infiltration of the esophageal epithelium. Over 50% of ...

The guidelines support use of PPIs, dietary therapy, and biologics for EoE, and stress the importance of addressing both the inflammatory and fibrostenotic aspects of the disease.

A multi-institutional study has identified one of the allergens responsible for eosinophilic esophagitis (EoE), an inflammatory disease of the esophagus. This is the first time one of the allergens ...

Eosinophilic Esophagitis predominantly affected males ... In January 2024, US FDA approved DUPIXENT (dupilumab) for the treatment of pediatric patients aged 1 to 11 years, weighing at least ...

Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological disease remission at 16 weeks compared to placebo, which was sustained up to ...

The Eosinophilic Esophagitis market report provides current treatment ... In January 2024, US FDA approved DUPIXENT (dupilumab) for the treatment of pediatric patients aged 1 to 11 years, weighing at ...

recommendations are presented for the diagnosis and management of eosinophilic esophagitis (EoE). Evan S. Dellon, M.D., M.P.H., from the University of North Carolina School of Medicine in Chapel ...